Nuvation Bio Inc. (NUVB) stock
NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30107% above fair value
$3.90+0.06 (+1.56%)
Close on Nov 17, 2026Market cap $1.37BP/E –Yield –
Nuvation Bio operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Nuvation Bio's operating cash flow for the twelve months ending Jun 30, 2026 was -$120.52M. For fiscal 2025 it was -$173.43M. The highest annual figure on record is -$36.53M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$173.43M | – |
| FY2024 | Dec 31, 2024 | -$130.41M | – |
| FY2023 | Dec 31, 2023 | -$68.00M | – |
| FY2022 | Dec 31, 2022 | -$96.11M | – |
| FY2021 | Dec 31, 2021 | -$68.19M | – |
| FY2020 | Dec 31, 2020 | -$36.53M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$42.97M | – |
| Q1 FY2026 | Mar 31, 2026 | $5.07M | – |
| Q4 FY2025 | Dec 31, 2025 | -$29.73M | – |
| Q3 FY2025 | Sep 30, 2025 | -$52.89M | – |
| Q2 FY2025 | Jun 30, 2025 | -$48.18M | – |
| Q1 FY2025 | Mar 31, 2025 | -$42.63M | – |
| Q4 FY2024 | Dec 31, 2024 | -$46.30M | – |
| Q3 FY2024 | Sep 30, 2024 | -$31.09M | – |
| Q2 FY2024 | Jun 30, 2024 | -$37.32M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.70M | – |
| Q4 FY2023 | Dec 31, 2023 | -$15.03M | – |
| Q3 FY2023 | Sep 30, 2023 | -$16.16M | – |
| Q2 FY2023 | Jun 30, 2023 | -$17.49M | – |
| Q1 FY2023 | Mar 31, 2023 | -$19.33M | – |
| Q4 FY2022 | Dec 31, 2022 | -$16.17M | – |
| Q3 FY2022 | Sep 30, 2022 | -$28.09M | – |
| Q2 FY2022 | Jun 30, 2022 | -$26.92M | – |
| Q1 FY2022 | Mar 31, 2022 | -$24.93M | – |
| Q4 FY2021 | Dec 31, 2021 | -$23.48M | – |
| Q3 FY2021 | Sep 30, 2021 | -$13.15M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.83M | – |
| Q1 FY2021 | Mar 31, 2021 | -$14.73M | -269.0% |
| Q4 FY2020 | Dec 31, 2020 | -$12.94M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.04M | – |
| Q2 FY2020 | Jun 30, 2020 | -$24.27M | – |
| Q1 FY2020 | Mar 31, 2020 | $8.72M | – |
See a number that looks wrong?